Sentences with phrase «lower drug prices»

Health and Human Services Secretary Alex Azar talked Friday about the administration's plans to lower drug prices as President Trump looked on in the White House Rose Garden.

Health and Human Services Secretary Alex Azar talked Friday about the administration's plans to lower drug prices as President Trump looked on in the White House Rose Garden.Chip Somodevilla / Getty Imageshide caption

Health and Human Services Secretary Alex Azar talked Friday about the administration's plans to lower drug prices as President Trump looked on in the White House Rose Garden.

Lastly, will Price continue to oppose allowing Medicare to negotiate with drug companies — a bid to lower drug prices — even though Trump has said he would support the idea?

Until the US government together with the Bill & Melinda Gates Foundation and UNITAID, an international organization that aims to lower drug prices, began subsidizing tests in 2012, each cost $ 16.86 (the price fell to $ 9.98), compared with a few dollars for a microscope TB test.

«Given his professional background, Sen. Murray will definitely want to focus on whether or not he will be able to make any effort to lower drug prices for patients,» says Mairead Lynn, spokesperson for ranking HELP Committee member Sen. Patty Murray (D - Washington).

When Pres. Donald Trump announced he was nominating Alex Michael Azar II to be the next secretary of health and human services, Trump called him a «star for better healthcare and lower drug prices.»

On the campaign trail Trump had called for action to lower drug prices, such as boosting medication imports and granting the government more negotiating powers to lower prescription costs.

This is a serious problem for many patients, and becoming a political topic (Lower Drug Prices: New Proposals Carry Lots of Promises, New York Times article from February 2018).

And last month the president promised Health and Human Services Secretary Alex Azar would unveil a host of proposals that would lower drug prices.

Its efforts to lower drug prices likely won't change much, and it probably knows that.

By acquiring Humana, Walmart gains preferential access to seniors through Humana Medicare advantage, and leverage over pharmaceutical manufacturers to negotiate for lower drug prices.

By adding a health insurance company in the form of Aetna, the resulting combination — retailer, clinic operator, pharmacy benefits manager, and insurer — can realize significant efficiencies, negotiate for lower drug prices with pharmaceutical manufacturers, and capture the growing share of healthcare spend among consumers and employers.

«He will be a star for better healthcare and lower drug prices!»

He pledged to lower drug prices, and White House Press Secretary Sean Spicer announced after the meeting that Amgen had promised to add 1,600 jobs.

House and Senate Democrats have introduced legislation aimed at lowering drug prices through a series of aggressive measures, including by requiring biopharma companies to reveal far more information about their R&D, manufacturing, and other costs.

In the afternoon, he will deliver remarks on lowering drug prices, after which he will meet with the Secretary of State.

Other actions recommended by respondents include showing social and environmental responsibility — by doing charity work, for example; fostering more collaborative research and funding more research; controlling costs and lowering drug prices; and demonstrating a commitment to safety.

Not exact matches

By contrast, while the cost of older, branded pharmaceuticals continue to rise and contribute to increased spending, when discounting is considered, prices of these drugs increased, on average, 2.8 % in 2015, the lowest growth rate in years.

According to Papa at this same Wells Fargo conference, he has not lowered the prices of Valeant's drugs.

They also said that they would lower the price of two heart medications, Nitropress and Isuprel, around 30 % (that's after raising the prices of the drugs 525 % and 212 %, respectively).

Express Scripts is one of the three massive PBMs that help negotiate lower prices for prescription drugs in the form of rebates on behalf of health plans.

Early Monday, Frazier resigned from the presidential council in protest, and Trump almost immediately took to Twitter, saying, «Now that Ken Frazier of Merck Pharma has resigned from President's Manufacturing Council, he will have more time to LOWER RIPOFF DRUG PRICES!»

CVS and Aetna argue that their deal will lower healthcare costs for employees of their large corporate customers, giving the company greater clout to negotiate down drug prices and better manage the use of those medicines.

Tree — who said the policy change restored a price support for growers by reintroducing a «federal risk premium» — told Business Insider that while consumers in states were marijuana was legal were probably used to a high - quality and tested product, he suspected cracking down on legal marijuana production and sales would incentivize trafficking of lower - quality marijuana to states where the drug is still illegal.

Teva said in a statement it would soon start producing a generic version of the drug that will be «priced significantly lower than Viagra,» which will result in «millions in savings to consumers» and «make this medication accessible to people who might otherwise not have been able to afford it.»

Plus, a handful of companies will typically all get approved to make a generic at once, which ideally creates competition in the marketplace and can sometimes result in even lower prices for those drugs.

He has repeatedly called for allowing Medicare to directly negotiate drug prices, which would be bad for the industry's bottom line, and he has advocated legalizing the importation of medicines from nations where prices are lower.

Although the FDA can't dictate prices or reject therapies over pricing concerns (they can only focus on safety and efficacy), the agency can encourage more competition through moves like this (as well as speedier approval pathways) which could spur drug makers to produce products that ultimately lower costs for patients — a goal cited by FDA Commissioner Scott Gottlieb in announcing the list.

Turing Pharmaceuticals, which raised the price of a drug 5,500 % practically overnight says it will now lower its price following an intense backlash from the media, medical profession and the general public.

Besides, if Mylan were to actually reduce the price of EpiPen, it would have ramifications other than just lowering what individuals pay for the drug.

The president followed up later in the day, tweeting that Merck «is a leader in higher & higher drug prices while at the same time taking jobs out of the U.S. Bring jobs back & LOWER PRICES!&prices while at the same time taking jobs out of the U.S. Bring jobs back & LOWER PRICES!&PRICES!»

In addition to the potential for medical breakthrough, most analysts who spoke with CNBC also noted that cancer drugs are not subject to increased political pressure to lower prices.

Compared to Pharmaprix, Shoppers Drug Mart's brand in Quebec, where cosmetics clerks aggressively shepherd shoppers to perfume counters and cashiers urge them to join the store reward program, a visit to a Jean Coutu is a low - key affair, with the focus firmly on low prices.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The whole industry faces turmoil with the advent of laws in several provinces demanding lower prices on generic drugs.

Initially, the company could buy drugs at a greater volume and demand lower prices,» Hobson said.

Roy Guharoy, chief pharmacy officer at 141 - hospital Ascension Health, said he didn't sign a contract from Valeant because it didn't promise to maintain lower prices on the drugs.

The «Yes on 61» campaign argues that Prop 61 would exploit the state's «bulk - purchasing power to secure lower prices for prescription drugs, saving taxpayers billions of dollars.»

The VA often pays the lowest prices for drugs in the nation, being able to negotiate what it pays for medications, often at a steep discount compared to other government agencies and Medicare.

HERERA: An expensive cholesterol drug is getting a price cut and while that may sound like a good thing the lower price wo n`t necessarily be available to everyone who wants the medicine.

Eleven of the hospitals or purchasing groups said they weren't yet getting lower prices on one or both drugs.

If Issue 2, or the Drug Price Relief Act, passes, the act would require the state and state agencies, including Ohio Medicaid, to pay the same or lower prices for prescription drugs as the U.S. Department of Veterans Affairs does.

Profit declines sharply and company cuts full - year outlook

Cardinal Health Inc. reported a sharp decline in profit in its last quarter and lowered its full - year outlook following inventory write - downs in its overseas businesses and a sharper - than - anticipated decline in generic drug prices.

As a result, the drug manufacturers end up setting two prices for their drugs — the higher list price and the lower, secret, «real» price that insurers pay.

And the revised deal will let Rite Aid buy generic drugs through a Walgreens affiliate, allowing the smaller chain access to the lower prices enjoyed by its bigger competitor.

Once a drug loses its patents, generic drug manufacturers start selling copycat versions at substantially lower prices.

The lawsuit claims that rather than competing with one another to offer a lower, «real» price to the insurers, the drug makers are vying to offer the best payment to the pharmacy benefit manager, which is why they have been raising the list price.

WASHINGTON (AP)-- Some low - cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.

It was unclear how extensively the three partners would overhaul their employees» existing health coverage — whether they would simply help workers find a local doctor, steer employees to online medical advice or use their muscle to negotiate lower prices for drugs and procedures.